{"paper_id":"a41de51f-0ff1-442f-bfc3-97f18fbef930","body_text":"1Scientific  RepoRtS  |         (2020) 10:5665  | https://doi.org/10.1038/s41598-020-62492-z\nwww.nature.com/scientificreports\nAuthor correction: Amine oxidase 3 \nis a novel pro-inflammatory marker \nof oxidative stress in peritoneal \nendometriosis lesions\nMarie-Laëtitia thézénas, Bianca De Leo, Alexis Laux-Biehlmann, cemsel Bafligil  , \nBernd elger, thomas t apmeier  , Karl Morten, nilufer Rahmioglu, Stephanie G. Dakin, \nphilip ch arles  , fernando estrada Martinez, Graham Steers, oliver M. fi scher, Joerg Mueller, \nHolger Hess-Stumpp, Andreas Steinmeyer, Sanjiv Manek, Krina t. Zondervan  ,  \nStephen Kennedy, christian M. Becker  , catherine Shang, thomas M. Zollner, \nBenedikt M. Kessler   & Udo oppermann  \nCorrection to: Scientific Reports https://doi.org/10.1038/s41598-020-58362-3, published online 30 January 2020\nIn Figure 5A, the chemical structure is incorrect. As a result, the Figure legend,\n“ AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.\n(A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2  mg/kg. (B) Unbound plasma levels \nof PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H2O2 in plasma. (E) \nPlasma exposure of PXS-4681A at day 2. (F ) Front/rear paw ratio measure using the dynamic weight bearing \nsystem indicating reduction of pain behaviour under treatment. ”\nshould read:\n“ AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.\n(A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthe-\nsized according to literature procedures\n37 (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target \nengagement results (2 mg/kg). (D) Changes in H2O2 in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) \nFront/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour \nunder treatment. ”\nThe correct Figure 5 and its accompanying legend appear below as Figure 1.\nPublished: xx xx xxxx\nopen\n\n\n2Scientific  RepoRtS  |         (2020) 10:5665  | https://doi.org/10.1038/s41598-020-62492-z\nwww.nature.com/scientificreportswww.nature.com/scientificreports/\nOpen Access This article is licensed under a Creative Commons Attribution 4.0 International \nLicense, which permits use, sharing, adaptation, distribution and reproduction in any medium or \nformat, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-\native Commons license, and indicate if changes were made. The images or other third party material in this \narticle are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the \nmaterial. If material is not included in the article’s Creative Commons license and your intended use is not per-\nmitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the \ncopyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.\n \n© The Author(s) 2020\nFigure 1. AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse \nmodel. (A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was \nsynthesized according to literature procedures37 (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg).  \n(C) Target engagement results (2 mg/kg). (D) Changes in H2O2 in plasma. (E) Plasma exposure of PXS-4681A \nat day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of \npain behaviour under treatment.","source_license":"CC0","license_restricted":false}